Kamran Alam - 12 Jan 2026 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Kamran Alam, Attorney-in-Fact
Issuer symbol
TSHA
Transactions as of
12 Jan 2026
Net transactions value
$0
Form type
4
Filing time
14 Jan 2026, 16:45:10 UTC
Previous filing
22 Aug 2025
Next filing
27 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Alam Kamran CHIEF FINANCIAL OFFICER C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, STE 1430, DALLAS /s/ Kamran Alam, Attorney-in-Fact 14 Jan 2026 0001793412

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Award $0 +359,000 +30% $0.000000 1,546,603 12 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Employee Stock Option (right to buy) Award $0 +231,000 $0.000000 231,000 12 Jan 2026 Common Stock 231,000 $4.86 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
F2 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.